Synairgen completes a successful equity placing to fund the company’s trial for COVID-19 patients
March 2020 — Synairgen plc has raised US$17.6 million to fund the company’s trial for COVID-19 patients.
Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the company uses in vitro and ex vivo models to progress opportunities into clinical development. The biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Our role in the transaction
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Synairgen on its oversubscribed equity fundraising to fund the company’s trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, manufacture of the drug and to strengthen the company’s balance sheet.
Talk to the deal team
Related deals
Heka Dental has joined forces with Impilo to anchor focused buy-and-build strategy
Heka Dental, a leading Danish designer and manufacturer of premium dental treatment units, has been acquired by the Swedish private equity firm Impilo. The acquisition establishes Heka Dental as a strategic platform for consolidation in the European dental equipment market. Impilo will execute a focused buy-and-build strategy to accelerate growth and expand its footprint across Europe.
Learn moreitemedical has been acquired by Halma
itemedical, a Netherlands-based provider of digital platforms that integrate real-time patient data and alarms from a wide range of medical devices to support clinical decision-making and workflow efficiency in hospitals, has been acquired by Halma plc, a global group of life-saving technology companies. The acquisition represents a milestone in itemedical’s development and provides a platform for its next phase of growth. By joining Halma’s healthcare sector as a business unit of Halma subsidiary Static Systems Group (SSG), itemedical will strengthen its position as a provider of digital hospital workflow solutions, benefiting from access to a global network of technology businesses, resources to accelerate innovation and opportunities to expand its international footprint.
Learn moreOEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value
OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.
Learn more